Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma

Y. Yumoto Radioisotope Center, Okayama University, Okayama, Japan

K. Jinno Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

K. Tokuyama Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

T. Wada Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

H. Kobashi Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

T. Okamoto Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

H. Toki Department of Internal Medicine, Shikoku Cancer Center Hospital, Matsuyama, Japan

S. Inatsuki Radioisotope Center, Okayama University, Okayama, Japan

K. Hara Department of Radiology, Shikoku Cancer Center Hospital, Matsuyama, Japan

S. Moriwaki Department of Radiology, Shikoku Cancer Center Hospital, Matsuyama, Japan

T. Tuji Department of Pathology, Shikoku Cancer Center Hospital, Matsuyama, Japan

H. Maeda The First Department of Internal Medicine, Okayama University School of Medicine, Okayama, Japan

show all

Abstract

The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver. After the oily carcinostatic agents were administered by Lp-TAE, HT, at a temperature of greater than 42.5°C, was induced for 40 min, twice a week by an RF of 8 MHz for a total of 10 to 38 times. The response rate was 40% in the 10 cases that were treated with Lp-TAE combined with HT and 20% in the 10 cases that were treated with Lp-TAE. The patients who were treated with Lp-TAE combined with HT had a tendency to have better survival rates than those of the Lp-TAE group (p <0.099). The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma

Information for

Open access

Opportunities

Help and information

Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature